Glen Eagle Advisors, LLC Cara Therapeutics, Inc. Transaction History

Glen Eagle Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.24 - $0.92 $24 - $92	-100 Closed	0 $0
Q4 2018 Aug 13, 2024	SELL	$12.45 - $23.47 $1,245 - $2,347	-100 Closed	0 $0
Q1 2018 Aug 14, 2024	BUY	$11.77 - $16.08 $1,177 - $1,607	100 New	100 $1.24 Million
Q4 2017 Aug 13, 2024	BUY	$11.86 - $14.08 $1,186 - $1,408	100 New	100 $1.22 Million
Q1 2017 Aug 12, 2024	SELL	N/A	-1,150 Closed	0 $0
Q4 2016 Aug 12, 2024	BUY	N/A	1,150	1,150 $10.7 Million

12.8M

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $14.5M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

Get notified when there are updates to the investment portfolio of Glen Eagle Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Glen Eagle Advisors, LLC with notifications on news.